Granted Patent B2

US 12,558,421 · App. 18/322,545 · Granted Feb 24, 2026

Inventors: Mark White (Antioch, CA); Sandeep Kumar (San Bruno, CA); Christopher Chan (South San Francisco, CA); Spencer Liang (San Mateo, CA); Lance Stapleton (Oakland, CA); Andrew W. Drake (Mountain View, CA); Yosi Gozlan (Tel Aviv, IL); Ilan Vaknin (Tel Aviv, IL); Shirley Sameah-Greenwald (Kfar Saba, IL); Liat Dassa (Tel Aviv, IL); Zohar Tiran (Oranit, IL); Gad S. Cojocaru (Tel Aviv, IL); Maya Kotturi (Belmont, CA); Hsin-Yuan Cheng (San Mateo, CA); Kyle Hansen (San Francisco, CA); David Nisim Giladi (Netaniya, IL); Einav Safyon (Raanana, IL); Eran Ophir (Even Yehuda, IL); Leonard Presta (San Francisco, CA); Richard Theolis (Santa Cruz, CA); Radhika Desai (Brisbane, CA); Patrick Wall (Mill Valley, CA)

Assignee: Compugen Ltd.

A61K39/39558A61K39/39541A61P35/00C07K16/2803C07K16/2809C07K16/2818C07K16/2827A61K2039/505A61K2039/507A61K2039/572C07K2317/21C07K2317/24C07K2317/33C07K2317/34C07K2317/522C07K2317/524C07K2317/526C07K2317/53C07K2317/55C07K2317/56C07K2317/565C07K2317/622C07K2317/732C07K2317/76C07K2317/92C07K2317/94C07K2319/035C07K2319/33Y02A50/30

Abstract

Claims (30)

1 . A nucleic acid composition comprising a first nucleic acid sequence encoding an amino acid sequence for a variable heavy domain of an anti-TIGIT antigen-binding domain and a second nucleic acid sequence encoding an amino acid sequence for a variable light domain of an anti-TIGIT antigen-binding domain, wherein the anti-TIGIT antigen-binding domain binds to human TIGIT (SEQ ID NO:97), wherein the anti-TIGIT antigen-binding domain comprises:

a) a variable heavy domain comprising vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO: 160; and

b) a variable light domain comprising vlCDR1, vICDR2, and vICDR3 from SEQ ID NO: 165.

2 . The nucleic acid composition according to claim 1 , wherein:

a) the first nucleic acid sequence comprises a sequence encoding a VH-CH1-hinge-CH2-CH3 amino acid sequence; and

b) the second nucleic acid sequence comprises a sequence encoding a VL-VC amino acid sequence, and the VC is either kappa or lambda.

3 . The nucleic acid composition according to claim 2 , wherein the amino acid sequence of the CH1-hinge-CH2-CH3 is selected from amino acid sequences for human IgG1, IgG2 and IgG4, and variants thereof.

4 . The nucleic acid composition according to claim 2 , wherein the hinge amino acid sequence optionally comprises one or more amino acid mutations.

5 . A nucleic acid composition comprising a first nucleic acid sequence encoding an amino acid sequence for a variable heavy domain of an anti-TIGIT antigen-binding domain and a second nucleic acid sequence encoding an amino acid sequence for a variable light domain of the anti-TIGIT antigen-binding domain, wherein the anti-TIGIT antigen-binding domain binds to human TIGIT (SEQ ID NO:97), wherein the anti-TIGIT antigen-binding domain comprises:

i) vhCDR1 comprising GFTFSSYA (SEQ ID NO: 161);

ii) vhCDR2 comprising ISYAGEVK (SEQ ID NO:162);

iii) vhCDR3 comprising ARDPLPLHYYGMDV (SEQ ID NO:163);

iv) vlCDR1 comprising SSNMGRRP (SEQ ID NO:166);

v) vlCDR2 comprising SQN; and

vi) vlCDR3 comprising AVWDDIGRVLQ (SEQ ID NO:168).

6 . A nucleic acid composition comprising a first nucleic acid sequence encoding an amino acid sequence for a variable heavy domain of an anti-TIGIT antigen-binding domain and a second nucleic acid sequence encoding an amino acid sequence for a variable light domain of an anti-TIGIT antigen-binding domain, wherein the anti-TIGIT antigen-binding domain binds to human TIGIT (SEQ ID NO:97), wherein the anti-TIGIT antigen-binding domain comprises:

a) a variable heavy domain comprising vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO: 150; and

b) a variable light domain comprising vlCDR1, vICDR2, and vlCDR3 from SEQ ID NO: 155.

7 . The nucleic acid composition according to claim 6 , wherein:

a) the first nucleic acid sequence comprises a sequence encoding a VH-CH1-hinge-CH2-CH3 amino acid sequence; and

b) the second nucleic acid sequence comprises a sequence encoding a VL-VC amino acid sequence, and the VC is either kappa or lambda.

8 . The nucleic acid composition according to claim 7 , wherein the amino acid sequence of the CH1-hinge-CH2-CH3 is selected from amino sequences for human IgG1, IgG2 and IgG4, and variants thereof.

9 . The nucleic acid composition according to claim 7 , wherein the hinge amino acid sequence optionally comprises one or more amino acid mutations.

10 . A nucleic acid composition comprising a first nucleic acid sequence encoding an amino acid sequence for a variable heavy domain of an anti-TIGIT antigen-binding domain and a second nucleic acid sequence encoding an amino acid sequence for a variable light domain of the anti-TIGIT antigen-binding domain, wherein the anti-TIGIT antigen-binding domain binds to human TIGIT (SEQ ID NO:97), wherein the anti-TIGIT antigen-binding domain comprises:

i) vhCDR1 comprising GFTFSSYA (SEQ ID NO: 151);

ii) vhCDR2 comprising ISYDGTPV (SEQ ID NO:152);

iii) vhCDR3 comprising ARDPLPLHYYGMDV (SEQ ID NO:153);

iv) vlCDR1 comprising SSNMGRRP (SEQ ID NO:156);

v) vlCDR2 comprising SQNSEQ ID NO: 157; and

vi) vlCDR3 comprising AVWDGDRRSLQ (SEQ ID NO:158).

Assignments (3)

Continuity (11)

References Cited (291)